RecruitingPhase 3NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Sponsor: Bristol-Myers Squibb
Canton, OH · Centerville, OH · Cincinnati, OH · +53 more sites